Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Momenta Pharmaceuticals Announces CAFC Decision to Invalidate Remanded Teva Pharmaceuticals Patent in Daily COPAXONE(R) 20 mg Suit
Fingolimod Therapy in Early Multiple Sclerosis: An Efficacy Analysis of the TRANSFORMS and FREEDOMS Studies by Time Since First Symptom.
Progress in multiple sclerosis research in the last year.
Rituximab induces clonal expansion of IgG memory B-cells in patients with inflammatory central nervous system demyelination.
Targeting insulin-like growth factor 1 leads to amelioration of inflammatory demyelinating disease.
Estimation of the effect of dalfampridine on health utility by mapping the MSWS-12 to the EQ-5D in multiple sclerosis patients.
"Tell me what you want, what you really really want….": asking people with multiple sclerosis about enhancing their participation in physical activity.
In vitro Biological Characterization of IFN-β-1a major Glycoforms.
Review of subcutaneous interferon β-1a, delivered via the electronic self-injection device RebiSmart™, for the treatment of multiple sclerosis.
A telerehabilitation program by virtual reality-video games improves balance and postural control in multiple sclerosis patients.
The effects of intrathecal rituximab on biomarkers in multiple sclerosis.
Direct demonstration of elevated aldehyde dehydrogenase in human hematopoietic progenitor cells.
Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis.
HERV-W envelope protein inhibits oligodendroglial precursor cell differentiation.
Benign Multiple Sclerosis: Does it exist?
Medical marijuana: clearing away the smoke.
The anti-VLA-4 antibody natalizumab induces erythroblastaemia in the majority of the treated patients with multiple sclerosis.
Different effects of opioid antagonists on mu-, delta-, and kappa-opioid receptors with and without agonist pretreatment.
Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: involvement of toll-like receptor 4 (TLR4).
Basis for fluctuations in lymphocyte counts in fingolimod-treated patients with multiple sclerosis.
Incidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndrome.
Identifying autoantigens in demyelinating diseases: valuable clues to diagnosis and treatment?
Celiac disease and multiple sclerosis in the northwest of Iran.
Active Biotech announce that European Medicines Agency accepts start of scientific review of the marketing authorization application for laquinimod in relapsing-remitting multiple sclerosis
Evaluation of Dalfampridine Extended Release 5 and 10 mg in Multiple Sclerosis: A Randomized Controlled Trial.

Pages